The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

BACKGROUND: Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer
Hauptverfasser: Werutsky, Gustavo, Maluf, Fernando Cotait, Cronemberger, Eduardo Henrique, Carrera Souza, Vinicius, dos Santos Martins, Suelen Patricia, Peixoto, Fábio, Smaletz, Oren, Schutz, Fábio, Herchenhorn, Daniel, Santos, Telma, Mavignier Carcano, Flavio, Queiroz Muniz, David, Nunes Filho, Paulo R. S., Zaffaroni, Facundo, Barrios, Carlos, Fay, André
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2019
Schlagworte:
Study Protocol
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6533731/
https://ncbi.nlm.nih.gov/pubmed/31122212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5709-y
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge